Printer Friendly

GENSIA AND SANDOZ SIGN AGREEMENT FOR DIABETES RESEARCH

 GENSIA AND SANDOZ SIGN AGREEMENT FOR DIABETES RESEARCH
 SAN DIEGO, Jan. 8 /PRNewswire/ -- Gensia Pharmaceuticals Inc. (NASDAQ: GNSA) and Sandoz Pharmaceuticals Corp. today announced the signing of a four-year agreement relating to the discovery, development and marketing of new drugs to treat Type II diabetes mellitus.
 In a joint announcement, the companies said the agreement would combine Gensia's novel technology for inhibiting the production of glucose with Sandoz's research and development expertise in diabetes.
 Under the agreement, Sandoz will fund basic research at Gensia directed toward the discovery of drugs for Type II diabetes mellitus. The Sandoz funding will support the discovery and development of compounds that regulate blood glucose production based on Gensia's technology for specifically inhibiting certain enzymes involved in the initial steps of glucose production in the body. Sandoz also may contribute compounds for evaluation, according to the agreement.
 Sandoz will have the right to an exclusive worldwide license to diabetes drugs discovered during the agreement and will be responsible for preclinical pharmacology, clinical development, regulatory filings, manufacturing and marketing of any compounds licensed for development.
 Gensia will receive milestone payments as drugs are developed. The overall value of the research and development agreement to Gensia is expected to be approximately $22 million if one drug is developed. Additional milestone payments would be paid to Gensia if more than one drug is developed and marketed.
 Gensia also has an option to co-promote in the United States and Canada any diabetes drug developed under the agreement and will receive royalty payments on the sale of any licensed drug where Gensia does not co-promote.
 "Preclinical research relating to Gensia's glucose-lowering technology suggests that certain compounds may decrease glucose production in liver cells through a novel mechanism," said David F. Hale, chairman, president and chief executive officer of Gensia.
 "We believe this technology may have application in the development of new drugs for the treatment of Type II diabetes mellitus, which affects an estimated 10 million people in the United States alone. Because of their condition, Type II diabetics face a higher risk of developing long-term complications, including kidney, eye, cardiovascular and certain neurological diseases," he said.
 At the Sandoz Research Institute, the research and development arm of Sandoz Pharmaceuticals, scientists are systematically pursuing research aimed at discovering innovative new drugs for the treatment of Type II diabetes mellitus.
 "The focus of this joint research and development program with Gensia complements and enhances the broad-based approaches and overall strategy pursued by Sandoz in its in-house program to identify a new generation of effective drugs for the treatment of this dread disease," said Robert I. Levy, M.D., president of the Sandoz Research Institute.
 Headquartered in East Hanover, N.J., Sandoz Pharmaceuticals Corp. is engaged in the research, development, manufacture and marketing of both over-the-counter (OTC) pharmaceuticals and prescription products for organ transplantation, mental and emotional disorders, headache and other pain states, hypertension, Parkinson's disease and cancer.
 Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases. Gensia currently has two cardiovascular drugs in late- state clinical trials, Arasine(TM) and arbutamine, part of the GenESA(TM) System.
 -0- 1/8/92 R
 /CONTACT: David F. Hale or Martha L. Hough of Gensia Pharmaceuticals Inc., 619-546-8300; or David L. Winter or William J. O'Donnell of Sandoz Pharmaceutical Corp., 201-503-7217/
 (GNSA) CO: Gensia Pharmaceuticals; Sandoz Pharmaceutical Corp. ST: California IN: MTC SU:


EH-KJ -- SD001 -- 7871 01/08/92 14:20 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 8, 1992
Words:585
Previous Article:1992 MOBIL TRAVEL GUIDE AWARDS FOUR STARS TO TWO UTAH PROPERTIES
Next Article:MAGMA COPPER CO. TO LIST ON NEW YORK STOCK EXCHANGE
Topics:


Related Articles
GENSIA AND SANDOZ SIGN AGREEMENT FOR DIABETES RESEARCH
GENSIA AND ALLERGAN ENTER INTO RESEARCH AGREEMENT IN OPHTHALMIC DISEASE
IMCERA'S MALLINCKRODT MEDICAL UNIT AND SANDOZ PHARMA LTD. SIGN AGREEMENT TO SHARE MOLECULAR RESEARCH
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
Gensia Sicor Appoints Sanofi Winthrop Exclusive Distributor for Brevibloc In U.K. and Ireland
Gensia Sicor Announces Supply Agreement With Value Oncology Sciences
Gensia Sicor Announces Collaboration With Sankyo in Diabetes Research
Gensia Laboratories Announces Five Year Product Development and Supply Agreement with SEQUUS Pharmaceuticals
Gensia Sicor and F.H. Faulding Announce International Product Licensing Agreement
Gensia Sicor and ASTA Medica Announce Peptide Depot Development Agreement

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters